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Abstract. A panel of tumour models used extensively for 
in vivo evaluation of new drugs was characterised for their 
p53 status. Basal p53 protein levels were measured by immuno­
detection on both formalin-fixed tumour tissue and from 
protein extracts of fresh tumours. High levels of nuclear-
specific staining, indicative of p53 mutation, was seen in 
15/25 tumours, with the remainder showing intermittent or 
no staining. The functional status of p53 cDNA from these 
tumours was assayed within the functional analysis of 
separated alleles in yeast (F.A.S.A.Y.) reporter system. The 
cDNA from those tumours with high levels of p53 protein 
showed 14/15 failing to activate the reporter gene. The 
cDNA from tumours with low or non-detectable p53 levels 
showed 8/10 with wild-type p53. Tumours were grown 
subcutaneously in mice (n=10). Each mouse was given 
maximum tolerated doses for either doxorubicin, 5-fluorouracil 
or cisplatin. Tumour volumes were measured daily, alongside 
untreated controls. The specific growth delay values for each 
tumour were separated into two groups, those with functional 
p53 (wild-type) and those without (mutant and null status). 
The Mann-Whitney U test was performed on the groups of 
data, to evaluate differences in their response on the basis of 
p53 status. Cisplatin was moderately active against tumours 
with wild-type and mutant p53 genes with no significant 
difference seen between both groups. However, a significant 
difference in specific growth delay was seen between the two 
groups when treated with doxorubicin or 5-fluorouracil 
(P=0.05), indicating a role for p53 protein in modulating the 
in vivo efficacy of these agents. 
Introduction 
Mammalian cells respond to DNA damage by activating cell 
cycle checkpoints that arrest the cell cycle at specific points 
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to allow DNA repair. P53 is a nuclear phosphoprotein that 
functions as a sequence specific transcription factor. P53 
protein is involved in cell cycle control, DNA repair, apoptosis, 
cellular differentiation and senescence (1). P53 regulates the 
G l checkpoint (2,3), where DNA damage activates p53 
protein leading to transactivation of the cyclin-dependent 
kinase inhibitor p21 W A F (4). Irrepairable DNA damage can 
trigger p53-dependent apoptotic pathways within the cell 
involving several p53-transactivated proteins e.g. bax (5), 
Fas/APO-1 (6), and many redox related genes (7). The lack 
of a functioning p53 may lead to the maintenance of cells 
with damaged DNA, from which genetic instability can 
occur. P53, therefore, preserves genome integrity and has 
been described as being the 'guardian of the genome' (8). 
Many of the chemotherapy agents used in the clinic have 
mechanisms that rely specifically on interaction with DNA. 
DNA damage will cause cell cycle arrest or apoptosis within 
these cells resulting in inhibition of tumour growth. One of 
the main pathways activated in response to DNA damage, 
being the activation of p53 protein. However, the p53 gene is 
found to be mutated in over half of all human cancers (9) and 
as a result, cells with p53 mutations may become resistant to 
these agents requ i r ing changes in prognost ic cl inical 
parameters and treatment choices within the clinic. 
Many methodologies are available for the analysis of p53 
gene alterations. In normal cells p53 has a short half-life and 
a rapid turnover (10). The mutant protein, however, has a 
greater stability and a longer half-life, causing accumulation 
of the protein within the nucleus. Immunodetect ion of 
increased p53 protein levels within tumour sections forms the 
basis of a screening technique that gives a generally good 
cor re la t ion (11) . H o w e v e r , the d i sadvan tages of this 
technique include the failure to distinguish between wild-type 
and null p53 status and also in revealing tumours with a 
heterozygous genotype. 
The p53 gene therefore requires a more precise analysis tool 
in order to fully characterise those tumours with dysfunctional 
p53. Direct DNA sequencing of the gene or cDNA would 
reveal all mutations, however, this is beyond the scope of 
many clinical laboratories and is too expensive for routine 
diagnostics. In this report the functional analysis of separated 
alleles in yeast (F.A.S.A.Y.) has been utilised (12-14). This 
reveals whether the p53 cDNA can encode for a functional 
p53 protein and identifies any tumours with heterozygous 
genotypes. 
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In many clinical studies, p53 mutation has been correlated 
with poor prognosis and shortened patient survival, especially 
studies in breast cancer (15). However, clinical biopsy samples 
are frequently characterised by immunodetection techniques 
alone that determine p53 mutation indirectly, and also primary 
tumours may display field clonality changes as p53 mutant 
clones appear from previously wild-type cells within a 
heterogeneous tumour environment during the course of the 
disease. The variables with such studies are multiple. P53 has 
not been shown to be a strong enough prognostic marker to be 
used in routine decision making for chemotherapy. The 
apparent failure of these studies may be due to many factors 
including the lack of suitable characterisation of patient 
tumours, lack of suitable controls e.g. untreated controls, lack 
of normalisation of dosing schedules and choices. 
Characterization of models used for drug development is 
important in determining targets and sensitivity modulators 
that may affect drug activity. The NCI cell line panel, used 
for the screening of anti-cancer compounds, previously 
showed a close correlation between cell line p53 status and 
chemosensitivity in vitro to certain chemotherapy agents (16). 
However, the in vitro setting is far removed from the more 
clinically relevant in vivo tumour models, as pharmacokinetic, 
pharmacodynamic and immunological effects are taken into 
account. Taking a step back from the clinic and examining the 
role of p53 within well-defined tumour models offers a more 
controlled setting than the clinical environment for treatment 
choices and controls and offers a significantly better realistic 
setting than that found in vitro. A well characterised panel of 
tumour models would therefore also be a more efficient and 
ethical tool for further in vivo testing of novel compounds. 
Here we report the characterisation of a panel of tumours, 
both human and murine, and their sensitivities to three agents 
used in the clinic, 5-fluorouracil, doxorubicin and cisplatin. 
These tumours represent useful tumour models with varying 
degrees of tissue type, differentiation, chemosensitivity, 
growth rates and aggressiveness. These three agents exert their 
cytotoxic activities through DNA interacting mechanisms and, 
as a result, the status of p53 within these tumours may have a 
profound effect on how they respond to these agents. The 
aims of this study were to determine whether p53 status 
alone does indeed modulate the sensitivity of tumours to 
these DNA damaging agents and to examine whether such 
correlations can be made within a more controlled tumour 
model environment, because if not, the hope of drawing such 
correlations within patients may be impossible. 
Materials and methods 
Tumours. Tumours grown subcutaneously were excised from 
mice and cut up into smaller pieces. Small tumour pieces 
were then implanted subcutaneously in mice using a trocar 
and allowed to grow until they reached a sufficient size. The 
procedure was performed under a project licence approved 
by the Home Office, London and U.K.C.C.C.R. official 
guidelines (17) were followed throughout. Tumour types and 
sources can be seen in Table I. 
Immunostaining for p53 overexpression. Formalin-fixed 
paraffin-embedded tumour tissue was cut at 6 mm thickness. 
Table I. The types and sources of the tumours used in the 
study. 
The sections were dewaxed in xylene and rehydrated 
through a series of alcohol (100-70%) and finally into 
distilled water. After washing in distilled water and then 
PBS (phosphate-buffered saline, pH 7.6) the sections were 
immersed for 15 min in 1% H202 in PBS, to quench any 
endogenous peroxidase activity. Following another 10 min 
wash in PBS the sections were immersed in 10 mM citric 
acid monohydrate buffer (pH 6.0), and microwaved for 5x5 
min (750 W) for antigen retrieval, ensuring that they were 
completely immersed in buffer throughout each microwaving 
treatment. Following microwaving the sections were allowed 
to cool to room temperature and were then transferred to PBS 
(pH 7.6) and washed for 5 min. All subsequent incubations 
were performed in PBS and carried out in a humidified 
chamber to prevent dehydration. Sections were then blocked 
using normal serum (Vector, Peterborough, U.K.) for 30 
min. The p53 protein was detected by using either DO-1 
mouse anti-human p53 monoclonal antibody (for human 
tumour sections) or CM-5 rabbit anti-mouse p53 polyclonal 
Name 
F9 
MAC 13 
MAC 15 
MAC 15 A 
MAC 16 
MAC26 
MAC29 
MAC30T 
MAC31 
MAC32 
COLO205 
DLD-1 
HT29 
HCC2998 
HCT116p53+/+ 
HCT116P53-'-
SW620 
H460 
H69 
MT-1 
MCF-7N 
NCI ADRR 
MT-3 
MDA-MB-435 
U87-MG 
A431 
Tumour type 
Mouse testicular carcinoma (18) 
Mouse adenocarcinoma of the colon (19) 
Mouse adenocarcinoma of the colon (19) 
Ascites cells of MAC15 (20) 
Mouse adenocarcinoma of the colon (21) 
Mouse adenocarcinoma of the colon (21) 
Mouse adenocarcinoma of the colon (21) 
Mouse adenocarcinoma of the colon (22) 
Mouse adenocarcinoma of the colon (21) 
Mouse adenocarcinoma of the colon (21) 
Human colon adenocarcinoma (23) 
Human colon adenocarcinoma (24) 
Human colon adenocarcinoma (25) 
Human colon adenocarcinoma 
(from NCI, original reference not given) 
Human colon adenocarcinoma (26) 
Human colon adenocarcinoma, 
p53 knock out (27) 
Human colon adenocarcinoma (28) 
Human lung carcinoma (29) 
Human lung carcinoma (29) 
Human mammary carcinoma 
(30 and refs. therein) 
Human mammary carcinoma (31) 
Adriamycin resistant cell line 
Human mammary carcinoma 
(30 and refs. therein) 
Human mammary carcinoma (32,33) 
Glioblastoma-astrocytoma (34) 
Epidermoid-squamous carcinoma (35) 
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antibody (for mouse sections) both from Novocastra 
(Newcastle upon Tyne, U.K.)- The Vectastain ABC kit 
(Avidin-Biotin Complex using horseradish peroxidase) 
obtained from Vector, was used for the detection of the 
primary antibodies, used at manufacturer's recommendations, 
using diaminobenzidine as the chromogenic substrate. The 
sections were counterstained with haematoxylin. After 
dehydration the sections were mounted in DPX and 
examined. 
Protein extraction from tumours. Whole tumours or tumour 
samples were collected from mice with subcutaneously 
implanted tumours during a routine passaging procedure. The 
tumours were immediately frozen in liquid nitrogen. The 
tissue was then sonicated on ice using a Semat 250 sonicator 
(Semat, St. Albans, UK), in the presence of protease inhibitors, 
at a maximum setting of 7 microns with 5x5 sec bursts to 
extract the protein. 
SDS-PAGE of protein samples. Samples, containing 30 (ig of 
protein, were loaded onto a polyacrylamide gel consisting of 
a 4% stacking gel and a 10% resolving gel. Proteins were then 
transferred to a nitrocellulose membrane by electroblotting 
apparatus. 
Western blotting. Non-specific protein binding was blocked 
by adding a solution of TBS (Tris-buffered saline) with 
Tween-20 (0.05%) containing 5% w/v non-fat dried milk. 
This was incubated with gentle agitation at room temp for 1 h. 
The membranes were then probed with DO-1, or CM-5, for 1 h 
at room temperature. The membrane was incubated with a 
1/2500 dilution of secondary HRP labelled antibody (Roche, 
Welwyn Garden City, UK) in blocking solution for at least 30 
min, followed by thorough washes in TBS-Tween-20 (0.05%). 
The membrane was then incubated in chemiluminescent 
substrate (ECL from Amersham Pharmacia Biotech, Little 
Chalfont, UK) for 1 min and light emission was captured using 
ECL hyperfilm (Amersham), developed according to the 
manufacturer's recommendations. Membranes were then 
stripped and reprobed with an anti-6-actin antibody (Sigma) to 
determine equal loading. 
RNA extraction and cDNA synthesis. Tissue samples were 
removed from mice with subcutaneous tumours during routine 
passaging and were immediately frozen in liquid nitrogen. 
Total RNA was purified using the Purescript RNA isolation kit 
(Gentra Systems, Minneapolis, USA), from between 5-10 mg 
of tissue ground with a microfuge pestle. The quality of the 
RNA was visually estimated by the presence of the 18S and 
28S rRNA bands upon electrophoresis with ethidium bromide 
stain. 
The RNA was reverse transcribed, using AMV (Avian 
myeloblastosis virus) reverse transcriptase (Roche, Welwyn 
Garden City, UK), into single stranded cDNA using an oligo-
p(dT) primer to select for poly(A) mRNA. The reaction was 
incubated at 25°C for 10 min to allow the primer to anneal and 
then at 42°C for 60 min for reverse transcription. To minimise 
interference with subsequent applications, the AMV reverse 
transcriptase was then denatured by heating at 99°C for 5 min. 
The reaction products were stored at -80fC. 
Amplification of p53 cDNA by PCR. The p53 cDNA was 
amplified by PCR using the following primers (Oswell, 
Southampton, UK). Human specific primers (13). Sense 5'-
ATT-TGA-TGC-TGT-CCC-CGG-ACG-ATA-TTG-AA(S)C-
3' Antisense 5'-ACC-CTT-TTT-GGA-CTT-CAG-GTG-GCT-
GGA-GT(S)G-3'. Mouse specific primers Sense 5'-ATC-
TGT-TGC-TGC-CCC-AGG-ATG-TTG-AGG-AG(S)T-3' 
Antisense 5'-ACC-CTT-TTT-GGA-CTT-CAG-GTG-GCT-
GGA-GT(S)G-3'. Where (S) represents a phosphorothioate 
linkage. 
PCR was performed for 35 cycles of 94°C for 30 sec, 
65°C for 60 sec and 78°C for 80 sec using a thermal cycler 
that had been preheated to 95 °C. The PCR mix was allowed a 
final extension at 74°C. 2 (il of the cDNA reaction product 
was amplified in 20 p.1 of Pfu buffer (Promega, Southampton, 
UK) plus 1.25 units of Pfu DNA polymerase, 100 ng of 
primers, 10% dimethyl sulphoxide, and 50 uM dNTPs. PCR 
controls included (i) negative control incubation without 
template DNA and (ii) positive controls included plasmids 
known to contain the p53 cDNA sequence. 
PCR reaction product (5 u.1) was then run on a 1.5% 
agarose gel, alongside a molecular weight marker, to check 
the PCR product. 
Vector preparation for transformation of yeast. The plasmid 
pSS16 (13) was obtained from Dr R. Iggo (I.S.R.E.C. 
Switzerland). 5 \x\ of plasmid (10 |ig approx) was cut by 
restriction digest using Stul and Hindlll. The linearised 
vector was then dephosphorylated using calf intestinal 
alkaline phosphatase (Sigma-Aldrich Company Ltd. Dorset, 
UK) at 37°C for 30 min. The linearised vector was gel 
purified using the Glassmax DNA isolation kit (Invitrogen, 
Paisley, UK) and redissolved in TE buffer (pH 8.3). 
Yeast transformation and growth. The yeast strain yIG397 was 
obtained from Dr R. Iggo (I.S.R.E.C. Switzerland) and was 
routinely cultured on complete medium (yeast extract, peptone, 
dextrose: YPD), supplemented with adenine at 10 x excess 
concentration (200 jag/ml), to avoid selection of spontaneous 
suppressors of the endogenous adel locus. The resulting 
colonies were all white in colour. Any red colonies would 
have been discarded (13). 
Transformation of competent cells. The EasyComp S.c. 
transformation kit (Invitrogen, Paisley, UK) was used to 
make the yeast competent, and was also used for the 
transformation. Linearised vector DNA (5 (il or 1 (tg) and 5 jai 
of PCR product was used for the transformation. The 
components were mixed by vortexing vigorously. The cells 
were then incubated for 1 h at 30°C, and again vortexed at 
15 min intervals during the incubation. Cells (100 (il) were 
plated on synthetic minimal media minus leucine, left to 
grow for 2-4 days at 30°C, and the number and colour of the 
yeast colonies were counted. 
Control transfections included transfection with linear 
vector only, pSS16 whole vector only, PCR product only. 
Untransfected cells were also grown on leucine plus and 
leucine minus media. PCR products from plasmids with 
known p53 status i.e. wild-type and known mutants were also 
transfected. 
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In vivo chemotherapy studies. Female NCR-Nu mice (NCI, 
Frederick, USA) for human tumours and NMRI pure strain 
mice (B&K, Hull, UK) for murine tumours aged 6-8 weeks 
were used for this study. Mice were kept in isolators at 23°C, 
under conditions of regular cycles of light and dark and given 
food (Standard rat and mouse feed from B&K, Hull, UK) and 
water, ad libitum. Experiments were performed under a 
project licence approved by the Home Office, London and 
U.K.C.C.C.R. official guidelines (17) were followed 
throughout. 
Tumours were grown subcutaneously in mice, and were 
ready for treatment when their diameters reached 2-4 mm. 
Mice were separated into treatment and control groups, each 
made up of 6-12 mice. Single dose drug treatments were 
given at predetermined maximum tolerated doses, 
(doxorubicin at 10 mg/kg, cisplatin at 6 mg/kg and 5-
fluorouracil at 125 mg/kg). Agents were dissolved in sterile 
saline and administered by intraperitoneal injection (IP) at 
their maximally tolerated doses. Control groups were 
injected IP with saline only. 
Tumours were measured at daily intervals using calipers 
and the tumour volume calculated using the formula for the 
volume of an ellipsoid, where a is equal to the smaller 
tumour diameter and b equal to the larger one. 
Relative tumour volume (RTV) for day 0 was given a value 
of 1. RTV for subsequent days was calculated by comparing 
Figure I. Sections of tumour tissue immunostained for p53. A, weak or absent staining in the MT-1 tumour; B, strong nuclear-specific staining seen in the 
COLO205 tumour; C, weak staining seen in the MAC15 tumour and D, strong nuclear-specific staining seen in the MAC32 tumour (s, stroma; t, tumour; v, 
blood vessel). Bar represents 50 um Immunostaining for p53 in the HCT116 p53+/+ tumour 24 hours after treatment with doxorubicin (10 mg/kg). E, 
represents a small tumour nodule showing the absence of a necrotic centre and an uniform distribution of nuclei staining for p53. F, represents a larger 
tumour, with a necrotic centre (N) and an area of surrounding cells showing no staining for p53, indicated with the arrow. O, indicates the outside edge of the 
tumour showing host skin cells and adipocytes. 
a2 x b = Tumour volume 
2 
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Table II. Summary of the characterisation data, including the immunodetection of protein levels and F.A.S.A.Y. functional 
analysis results for each tumour type. 
the tumour volume to the volume on day 0. The time taken 
for the tumour volume to double, RTV 2 was calculated and 
the significance of any delays in tumour growth between 
mean values of the control and treated groups was determined 
by use of the Mann-Whitney U-test. 
Correlation between p53 status and the growth delay 
observed with the standard agents - statistical analysis. The 
specific growth delay (SGD) for each treated tumour was 
measured using the following formula, where T'2 is the time 
taken for the treated tumour to double, and the T2 is the time 
taken for the (untreated) control to double in volume (36). 
This allowed the responsiveness of a panel of tumours 
which differ in growth rate, to be compared. The tumour 
lines were separated into two groups; wild-type and mutant. 
The statistical significance between the mean specific growth 
delay for both groups was then determined by the Mann-
Whitney U-test using SPSS software. 
Results 
Immunodetection of protein levels. Basal levels of the p53 
protein were determined from formalin-fixed tumour tissue 
sections and also from protein extracts from fresh tumour 
tissue, using the DO-1 and CM-5 antibodies. Three basic 
patterns of immunostaining were observed, i) strong nuclear-
specific staining, ii) weak staining in some nuclei, and iii) no 
detectable protein. Fig. 1A-D gives examples of the types of 
staining patterns observed, from both human and murine 
tumours. Normal, i.e. wild-type, background levels of p53 
protein was not detected using the titres used here, as shown 
in the non-staining host tissues e.g. endothelial cells, skin 
cells etc. The results are summarised in Table II. 
The Western blot analysis complemented the immuno­
staining results and gave a clear band of 53 kDa (approx). 
An extract from E. coli transfected with a human p53 
Name 
F9 
MAC 13 
MAC15A 
MAC 15 
MAC 16 
MAC 26 
MAC 29 
MAC 30T 
MAC 31 
MAC 32 
COLO 205 
HCC2998 
HCT 116 
HCT116p53'-
SW620 
DLD-1 
HT29 
A431 
U87-MG 
H460 
MT-1 
MT-3 
MCF-7N 
NCI ADRR 
MDA-MB-435 
Tumor type 
Mouse testicular carcinoma 
Mouse adenocarcinoma of the colon 
Mouse adenocarcinoma of the colon 
Mouse adenocarcinoma of the colon 
Mouse adenocarcinoma of the colon 
Mouse adenocarcinoma of the colon 
Mouse adenocarcinoma of the colon 
Mouse adenocarcinoma of the colon 
Mouse adenocarcinoma of the colon 
Mouse adenocarcinoma of the colon 
Human colon adenocarcinoma 
Human colon adenocarcinoma 
Human colon adenocarcinoma 
Human colon adenocarcinoma 
Human colon adenocarcinoma 
Human colon adenocarcinoma 
Human colon adenocarcinoma 
Epidermoid-squamous carcinoma 
Human glioblastoma-astrocytoma 
Human lung carcinoma 
Human mammary carcinoma 
Human mammary carcinoma 
Human mammary carcinoma 
Human mammary carcinoma 
Human mammary carcinoma 
Immunostaining 
description 
-i-ve, nuclear specific 
+ve, nuclear specific 
-ve staining 
-ve staining 
+ve, nuclear specific 
-ve staining 
+ve, nuclear specific 
-i-ve, nuclear specific 
+ve, nuclear specific 
+ve, nuclear specific 
+ve, nuclear specific 
-ve staining 
-ve staining 
-ve staining 
+ve, nuclear specific 
-i-ve, nuclear specific 
-i-ve, nuclear specific 
+ve, nuclear specific 
-ve staining 
-ve staining 
-ve staining 
Intermittent staining 
-ve staining 
+ve, nuclear specific 
+ve, nuclear specific 
Band present 
on Western blot 
Yes 
Yes 
No 
No 
Yes 
Weak 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
No 
Yes 
Yes 
Functional 
p53 
Yes 
No 
Yes 
Yes 
No 
Yes 
No 
No 
No 
No 
No 
No 
Yes 
NA / null 
No 
No 
No 
No 
Yes 
Yes 
Yes 
Heterozygous 
Yes 
No 
No 
Status 
WT 
MUT 
WT 
WT 
MUT 
WT 
MUT 
MUT 
MUT 
MUT 
MUT 
MUT/NULL 
WT 
NULL 
MUT 
MUT 
MUT 
MUT 
WT 
WT 
WT 
i WT/MUT 
WT 
MUT 
MUT 
SGD = T2-T2 
T'2 
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Figure 2. An example of the Western blot analysis done on protein extracts 
from fresh tumour tissue. The positive control included transfected E. coli 
cells expressing human p53 from a p53 expression construct. A clear single 
band is seen for p53 from the SW620 tumour whilst the HCT116 tumour did 
not produce a band for p53, from an equal loading of 30 \\.g of protein. 
expression construct, was used as a positive control. A clear 
band was seen for 15/25 tumours with the remainder 
showing very weak bands or no detectable protein. Fig. 2 
illustrates an example of the Western blot analysis. The 
results are summarised in Table II. 6-actin levels did not 
fluctuate between the tumour types. 
Tumours were separated into two groups according to the 
levels of p53 protein, i) those with high levels of protein and ii) 
those with low or undetectable levels and 15/25 were classed 
as having overexpression of p53 protein. 
P53 Functional Assay (F.A.S.A.Y.). A<ie2-cells grown on 
medium containing limiting adenine turn red because of an 
accumulation of an adenine metabolic intermediate (13). The 
yeast strain yIG397 contains a plasmid with the adel gene 
under the control of a p53 promoter. When the yeast is 
transfected with the cDNA from a wild-type p53 gene, the 
yeast cells express ade2, and grow normally as white 
colonies on minimal synthetic defined agar. Cells transfected 
with the cDNA from a mutant tumour, fail to transactivate 
the adel gene and grow to form red colonies. Plasmids 
containing wild-type and mutant p53 cDNA sequences were 
used as controls for the assay. These gave approximately 600 
colonies per plate. The cDNA from the tumours gave a lower 
transformation efficiency of approximately 400 colonies per 
plate. A small percentage of white colonies was seen 
amongst the mutant plates, and a small percentage of red 
colonies was seen amongst the white wild-type colonies. The 
percentage of yeasts transfected with-wild-type cDNA gave 
95% white colonies and yeasts transfected with mutant 
cDNA gave 99% red colonies. Numbers were sufficiently 
high as not to be significantly affected by the small percentage 
of differently coloured colonies presumably caused by a 
small percentage of wild-type host cells. Of the 25 tumours 
14 showed non-functional p53 cDNA, with 1/25 being 
heterozygous, 1/25 known to be null (HCT116 p53v) and the 
remainder having functional p53 cDNA. The results are 
summarised in Table II, and examples of the yeast colonies 
obtained from both wild-type and mutant tumours can be 
seen in Fig. 3. 
In vivo studies. We investigated whether p53 status could 
explain the differences in the sensitivity of the panel of 
tumours used at this laboratory, to the standard chemo-
therapeutic agents 5-fluorouraciI, doxorubicin and cisplatin with 
respect to their vehicle treated control. A summary of the data is 
given in Table III. The mean specific growth delay (SGD) 
response of the tumours to each agent was plotted and separated 
Figure 3. Results of the F.A.S.A.Y. analysis of tumour cDNA. A, yeasts transfected with the cDNA from the COLO205 tumour, showing non-functional p53 
and red colonies. B, yeasts transfected with the cDNA from the HCT116 tumour, showing functional p53 and white colonies. 
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Table III. Summary of the response of tumours to the maximum tolerated doses of the agents 5-fluorouracil, doxorubicin and 
cisplatin as compared to their untreated controls. The results represent the mean values from n=10-12 tumours indicating 
doubling times, growth delay, specific growth delays for each tumour type. 
into wild-type and mutant groups (Table II and Fig. 4). The 
median SGD for doxorubicin and 5-fluorouracil was 
significantly longer in the wild-type groups of tumours than in 
the mutant group giving Mann-Whitney U test value of <0.05, 
Table IV. Cisplatin did not produce a significantly longer SGD 
in either group being equally active against both groups of 
tumours (>0.05), Table IV. 
Staining for p53 in treated tumours. The HCT116 p53+/+ 
tumour was used to monitor the effect of doxorubicin within 
Tumour cell line 
Doxorubicin 
DLD-1 
SW620 
HCC2998 
HCT116p53+/+ 
HCT116p53'' 
H460 
U87-MG 
MAC 15 A 
MAC 16 
MAC26 
MAC29 
MAC30 
5-fluorouracil 
DLD-1 
SW620 
HCC2998 
HCT116p53+/+ 
HCT116P53-'-
H460 
U87-MG 
MAC 15 A 
MAC 16 
MAC26 
MAC29 
MAC30 
Cisplatin 
DLD-1 
SW620 
HCC2998 
HCT116 p53+/+ 
HCT116 p53-'-
H460 
U87-MG 
MAC15A 
MAC 16 
MAC26 
MAC29 
MAC30 
F9 
Mean doubling time, 
(days) of untreated tumours 
4.9 
2.6 
3.4 
2.5 
1.5 
1.8 
12.85 
1.57 
10.64 
1.97 
2 
3.87 
8.2 
2.55 
3.81 
3.5 
3.4 
4.7 
12.85 
2.44 
3.5 
3.3 
5.8 
4.8 
4.9 
2.6 
3.4 
4.2 
5.2 
1.8 
12.85 
2.4 
4 
3.3 
2 
4.8 
1.42 
Mean doubling time 
(days) of treated tumours 
5.3 
6.7 
4.3 
6.1 
2.3 
17.1 
21.26 
4.04 
11.34 
5.45 
3.2 
4.24 
9.2 
2.68 
7.03 
8.5 
4.5 
6.17 
14.85 
7.4 
4.3 
7.1 
6.1 
8.5 
6.9 
4.7 
6.0 
5.3 
5.5 
3.6 
16.9 
6.6 
9 
11.7 
11.5 
12.1 
7.93 
Mean growth 
delay (days) 
0.4 
4.1 
0.9 
3.6 
0.8 
15.3 
8.41 
2.47 
0.70 
3.48 
1.2 
0.37 
1.0 
0.13 
3.22 
5.0 
0.9 
1.47 
2 
4.96 
0.8 
3.8 
0.3 
3.7 
2 
2.1 
2.6 
1.1 
0.3 
1.8 
4 
2.2 
5 
8.4 
9.5 
7.3 
6.5 
Mean specific growth 
delay (days) 
0.08 
1.50 
0.26 
1.44 
0.44 
8.50 
0.65 
1.57 
0.06 
1.77 
0.60 
0.09 
0.04 
0.05 
0.84 
1.38 
0.27 
0.31 
.13 
2.03 
0.01 
1.15 
0.05 
0.77 
0.40 
0.81 
0.77 
0.26 
0.05 
1.00 
0.23 
0.91 
1.5 
2.54 
4.75 
1.52 
5.09 
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Wild type 
Figure 4. Boxplots showing the mean specific growth delays for each of the tumours tested separated into two groups, wild-type and mutant p53 status. Bars 
represent the median of the values. Box represents the upper and lower 25% quartiles. Outliers are shown (0). Figures represent data from 6-12 individual 
tumours for each type. 
Table IV. Results of the Mann-Whitney U test for non-parametric analysis of the mean specific growth rates for wild-type p53 
versus mutant p53 tumours. 
"indicates significant difference. 
the tumours. Treated tumours were excised at 12 h intervals 
and then p53 was detected on tumour sections. An upregulation 
of p53 was observed at around 24 h post treatment. The pattern 
of p53 staining, however, was not uniform throughout the 
tumour. Small tumour nodules showed an even distribution 
of cell nuclei staining for p53 across the section (Fig. IE), but 
larger tumours showed a region of cells surrounding the 
necrotic centre which did not stain for p53 (Fig. IF). 
Discussion 
This study reports the p53 status of a panel of tumour models 
used in drug discovery and their responsiveness to three 
standard agents in vivo. Assessment of basal p53 protein 
levels within the tumours was determined by two immuno­
detection methods, staining and Western blotting. Both 
methods gave similar results. Fifteen out of 25 tumours 
Agent 
Doxorubicin 
5-fluorouracil 
Cisplatin 
Mean specific growth 
delay (days) for wild-type 
tumours 
2.78 ±3.2 
1.00 + 0.70 
1.67 ±1.60 
Mean specific growth 
delay (days) for mutant 
tumours 
0.43 ± 0.40 
0.26 ± 0.30 
1.40 ±1.57 
P-value from 
Mann-Whitney 
test 
<0.05a 
<0.05a 
>0.05 
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showed overexpression of p53. The yeast assay provided a 
means of assaying the functionality of the p53 cDNA from 
the tumour panel. Fourteen out of 25 tumours possessed 
cDNA that encoded for non-functional p53 protein, and these 
were included in the 15/25 found to overexpress p53 protein. 
One tumour overexpressing p53 protein showed a heterozygous 
genotype. The HCT116 p53"'- tumour had no gene (or cDNA) 
for p53 to assay and showed no p53 protein as expected. The 
HCC2998 tumour showed no p53 protein upon immuno­
detection but showed conflictingly non-functional p53 genes 
in the assay, indicating the possibility of a silencing, or a stop 
mutation. Indeed this cell line was classified as possessing a 
213R/STOP mutation by the NCI (16). The remainder of the 
tumours possessed functional p53. 
The immunodetection methodologies and the F.A.S.A.Y. 
analysis show, in this sample of tumours, that the tumours 
with p53 protein overexpression are indeed of mutant p53 
status. However, the study also showed that not all tumours 
with low or undetectable p53 had wild-type p53 status. 
Therefore, immunodetection alone was not sufficient for the 
full analysis of p53 status, and must be coupled to a functional 
assay or sequencing protocol to be completely accurate. 
It should be noted that many other pathways exist that can 
influence wild-type p53 activity within the cell. Mdm5 
protein acts to inhibit p53 activity and is overexpressed in 
certain cancers, but these are rare and are not frequently 
found in the tissue types of the tumours studied here. In fact 
MDM5 overexpression was not found in any of the tumours 
studied (data not shown). The authors acknowledge that the 
Arf protein also modulates p53 activity but has not been 
studied in this panel of tumours. Also the panel of tumours 
tested were of known primary source which were known not 
to be associated with viral oncogenesis. 
Our aim was to determine whether the p53 status of the 
tumours was an important factor in the sensitivity and 
response to the standard anti-tumour agents 5-fluorouracil, 
doxorubicin and cisplatin. These agents are clinically 
relevant and influence DNA, through various mechanisms. 
DNA damaging mechanisms may require or may activate a 
p53 pathway within the cells. The p53 tumour suppressor has 
been shown to modulate the effects of many cytotoxic agents 
including 5-fluorouracil (37), and doxorubicin (38) whereas 
the effect of p53 on cisplatin activity is ambiguous and 
remains to be fully elucidated. One would therefore expect 
these agents to exhibit a better anti-tumour activity towards 
the wild-type tumours rather than the mutant tumours. This 
was indeed the case for doxorubicin and 5-fluorouracil but 
was not the case for cisplatin. Cisplatin showed an equal 
activity towards wild-type and mutant cell lines. The specific 
growth delay obtained with cisplatin was as long as that 
obtained in the wild-type tumours with doxorubicin and 5-
fluorouracil, and was longer than that obtained from the 
mutant groups with these agents. This may indicate that 
doxorubicin and 5-fluorouracil may require wild-type p53 for 
activity, whereas cisplatin may not. The apparent sensitivity of 
some colon tumours (with mutant p53) to cisplatin treatment 
e.g. MAC29, was surprising given that many of them were very 
resistant to doxorubicin (sensitivities being similar to that of 
the testicular tumour F9). However, some colon tumours with 
wild-type p53 showed resistance to cisplatin. These data 
would indicate a common, non-wtp53, cisplatin-sensitivity 
marker in these tumours, which could warrant further study. 
These results may indicate that p53 has no role in co­
ordinating the response of tumours to cisplatin. The mechanism 
of action of cisplatin is associated with components of the 
mismatch repair pathway and microsatellite instability (39). 
However, the role of p53 in modulating various elements of 
the DNA repair pathways has not been fully elucidated 
either. The p53 tumour suppressor is thought to modulate the 
activities and timing of the DNA repair response for example 
the nucleotide excision repair pathway (40) and the global and 
transcription-coupled repair pathways (41,42). Therefore, the 
role of p53 in the mechanism of cisplatin activity may be 
more subtle. Also, p53-mediated sensitivity to cisplatin may 
be cell-type specific. Some cells may undergo apoptosis in 
response to p53 induction whereas others may undergo cell 
cycle arrest. Cisplatin sensitivity has been observed in cell 
types not inherently prone to p53-mediated apoptosis when 
they have been disrupted for p53 function (43,44). 
In this study, 2 of the tumours represented a pair of 
isogenic cell lines HCT116 p53+/+ and HCT116 p53v' obtained 
from Dr B. Vogelstein, Baltimore, USA. The wild-type cell 
line HCT116 p53+/+ showed a better response and longer 
specific growth delay with the agents doxorubicin and 5-
fluorouracil, but both cell lines were resistant to cisplatin. The 
results seen with the p53 isogenic pair of cell lines reflected 
the general pattern seen in the whole panel of tumours. 
The HCT116 p53+/+ tumour served as a good model that 
highlights the problems associated with chemotherapy and 
predicting treatment outcome. This tumour being wild-type 
for p53 initially showed a good response to doxorubicin with 
tumour growth being significantly slower than the isogenic 
tumour HCT116 p53~'\ The amount of cells staining for p53 is 
also maximal at this time. However, the p53 staining of 
treated tumours shows that doxorubicin has had no effect on 
the cells towards the centre of the tumour, in those cells 
surrounding the necrotic centre. This could be due to several 
reasons e.g. poor vascular supply/drug delivery, high interstitial 
pressure, less percentage of cycling cells etc. These are the 
population of cells which could be responsible for the re-
growth of the tumour once the drug has been cleared, a 
situation very likely to be encountered in the clinic. 
Future work in this field would include the closer 
examination of the treated tumours themselves. The in vivo 
growth study used here cannot differentiate whether the cells 
within the tumours are undergoing cytotoxicity by apoptosis 
or necrosis, or are merely undergoing growth arrest and repair. 
Further histological analysis should therefore be undertaken. 
One would expect the inactivation of a protein with such 
a complex variety of functions within the cell, such as p53, to 
associate with a strong resistance to anti-tumour agents and 
the detection of mutations within patient tumours to strongly 
correlate with poor outcome to chemotherapy. Although some 
studies have shown such correlations, many have not or have 
not proved p53 to be a clinically useful marker, reviewed in 
(15). The correlations found in vitro reflect the relative 
simplicity of that setting, and accounts for the strong 
correlations found, but they do not mirror the more complex 
clinical setting, especially the three-dimensional nature of the 
drug-tumour interaction. The tumour models used in this 
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study mirror the clinical setting much more closely, and they 
have shown themselves to be a useful system in determining 
how the properties and function of one gene/protein, namely 
p53 does have an effect on how these tumours respond. 
However, the correlations found here show that the p53 
tumour suppressor seems to co-ordinate the response of 
tumours to some agents and not others. Although the extent 
of control over the variables in this study may not be possible 
in the clinic e.g. dosing times etc. These results indicate that 
p53 status can be useful as a prognostic or predictive marker, 
for the use of 5-fluorouracil and doxorubicin. The majority of 
the tumours used here were of colon origin, and the apparent 
lack of activity of 5-fluorouracil and doxorubicin against the 
group of tumours with mutant p53 , suggests that their 
usefulness within the clinic may be limited to the wild-type 
tumours. Wild-type tumours showed a wide variation in 
responsiveness within this panel towards 5-fluorouracil and 
doxorubicin, however the mutant tumours showed a much 
reduced response with a narrow range of variation. Therefore, 
with regard to clinical decision making, it is likely that p53 
would be more useful as an indicator of which tumours will 
not respond to a particular form of therapy, rather than being 
a prognostic marker. The results shown here are only relevant 
to primary tumours or large single metastatic deposits, not to 
small widely distributed metastasis. Therefore, these results 
cannot act as a prognostic indicator as the tumours used do not 
mirror the progression of the disease within a patient, they are 
a prognostic marker for a one tumour system. Although 
future work could bring in a more complex mouse-oriented 
tumour metastasis model. 
In conclusion, this study describes the p53 status of 
tumours used in drug development and the different role the 
p53 tumour suppressor has in modulating the sensitivities of 
these tumours to different chemotherapy agents. Not only 
will these results be useful in investigating the role of p53 
status on in vivo response to novel agents, but they may be 
useful in the detection and development of agents with novel 
non-DNA damaging (non-p53) activities, reducing the use 
of DNA damaging agents that eventually select for p53 
mutations. 
The status of tumour biopsies could be fully characterised 
for their p53 status by the techniques utilised in this study at 
time of diagnosis and throughout course of the disease, and the 
responsiveness of the tumours to various forms of therapy could 
be followed. In this way better use will be made of molecular 
profiling of tumours to aid in clinical decision making. 
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